Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances

Area of Science:

• Hepatology and Pharmacology
• Immunology and Molecular Biology

Background:

• Liver fibrosis is a significant scarring process resulting from chronic inflammation and injury.
• It is associated with prevalent conditions like viral hepatitis, alcoholic liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD).
• Current antifibrotic therapies are limited, with a lack of effective targeted treatments.

Purpose of the Study:

• To systematically review the molecular mechanisms driving liver fibrosis.
• To focus on recent advancements in drug treatments for hepatic fibrosis.
• To discuss etiological treatments, secondary prevention, and pharmacological options for common hepatitis leading to fibrosis.

Main Methods:

• Systematic literature review of molecular mechanisms.
• Analysis of preclinical and clinical data on emerging antifibrotic drugs and immunomodulators.
• Review of pharmacological treatments for hepatitis and liver fibrosis.

Main Results:

• Emerging antifibrotic drugs and immunomodulators show promise in preclinical studies.
• Some novel therapies have progressed to clinical research phases.
• A comprehensive understanding of molecular mechanisms is crucial for targeted treatment development.

Conclusions:

• Targeted antifibrotic therapies and immunomodulators represent a promising frontier for liver fibrosis treatment.
• Addressing the root causes of liver injury and implementing secondary prevention are vital.
• Further research and clinical trials are necessary to translate preclinical findings into effective patient care.